Quantum-Si’s New Preprint Showcases Advances in Protein Variant Detection using ProteoVue™ Software with Next-Generation Protein Sequencing™
December 20 2024 - 8:00AM
Business Wire
Announces early access availability of
ProteoVue Software
ProteoVue is part of broader set of innovation
initiatives, including the Company’s recently announced
collaboration with NVIDIA, to leverage AI to enhance sequencing
performance
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced a
new paper that was submitted to BioRxiv, demonstrating the
capabilities of its proprietary bioinformatics tool called
ProteoVue, for detecting and quantifying Single Amino Acid Variants
(SAAVs). The paper, titled “Detecting Amino Acid Variants Using
Next-Generation Protein Sequencing (NGPS),” highlights the
transformative potential of Quantum-Si’s Platinum® benchtop
instrument in advancing proteomics research and applications. The
full preprint publication will be available soon on the BioRxiv
website.
ProteoVue is an advanced analysis workflow within the Platinum
Analysis Software, designed to detect and quantify amino acid
variants in complex protein systems. ProteoVue’s capabilities
enable detecting a broad variety of protein variation including
isobaric variations, quantifying post-translational modifications,
and characterizing proteins with unnatural amino acids. ProteoVue
empowers cutting-edge research in proteoform science and protein
therapeutics.
“ProteoVue is a major step forward in harnessing the power of
Next-Generation Protein Sequencing,” said Jeff Hawkins, President
and Chief Executive Officer of Quantum-Si. “This innovation
showcases how our NGPS™ platform enables precise and scalable
proteomic analysis, providing researchers with tools to better
uncover protein variations critical for understanding biology and
disease.”
The paper establishes ProteoVue as a comprehensive tool for SAAV
detection and quantification. Using Quantum-Si’s NGPS technology,
ProteoVue leverages advanced signal processing, neural
network-driven kinetic signature modeling, and a robust clustering
framework to provide unparalleled insights into protein variants,
including those traditionally undetectable by mass
spectrometry.
Key Findings:
- Single Molecule Variant Detection: ProteoVue demonstrates the
ability to detect and quantify amino acid variants through
real-time measurement of individual protein molecules.
- Detection Across Variant Types: The pipeline differentiates
between different variant types by measuring change in single
molecule kinetic features associated with a variant.
“This paper underscores the potential of ProteoVue to support
advanced research in biomarker discovery, precision medicine, and
proteomics” said John Vieceli, Chief Product Officer at Quantum-Si.
“The work described here is part of our broader effort to
continually enhance NGPS analysis pipelines for customers. Our
proprietary analysis tools, combined with our collaboration with
NVIDIA, will enable us to further leverage AI and GPUs to process
the large volume of data expected to be produced across our
instrument portfolio, including the recently announced next
generation platform, Proteus.”
The Company previously announced a collaboration relationship
with NVIDIA as part of its Investor & Analyst Day on November
20, 2024 which introduced the Proteus platform and other
advancements.
Quantum-Si invites researchers and potential collaborators to
early access of the ProteoVue workflow. To learn how you can become
part of the journey toward deeper understanding and groundbreaking
discoveries, visit: Protein Variant Applications.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company’s
Platinum® instrument enables Next-Gen Protein Sequencing™ that
advances proteomic research, drug discovery, and diagnostics beyond
what has been possible with existing proteomic tools. Learn more at
quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of the Company may differ from its expectations, estimates,
and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
“anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,”
“believes,” “predicts,” “potential,” “continue,” and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation, the
Company’s expectations with respect to future performance and
development and commercialization of products and services, its
anticipated cash runway and its financial guidance for the full
year 2024. These forward-looking statements involve significant
risks and uncertainties that could cause the actual results to
differ materially from those discussed in the forward-looking
statements. Most of these factors are outside the Company’s control
and are difficult to predict. Factors that may cause such
differences include, but are not limited to: the inability to
maintain the listing of the Company’s Class A common stock on The
Nasdaq Stock Market; the ability of the Company to grow and manage
growth profitably and retain its key employees; the Company’s
ongoing leadership transitions; changes in applicable laws or
regulations; the ability of the Company to raise financing in the
future; the success, cost and timing of the Company’s product
development and commercialization activities; the commercialization
and adoption of the Company’s existing products and the success of
any product the Company may offer in the future; the potential
attributes and benefits of the Company’s commercialized Platinum®
protein sequencing instrument and kits and the Company’s other
products once commercialized; the Company’s ability to obtain and
maintain regulatory approval for its products, and any related
restrictions and limitations of any approved product; the Company’s
ability to identify, in-license or acquire additional technology;
the Company’s ability to maintain its existing lease, license,
manufacture and supply agreements; the Company’s ability to compete
with other companies currently marketing or engaged in the
development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have
greater financial and marketing resources than the Company; the
size and growth potential of the markets for the Company’s products
and services, and its ability to serve those markets once
commercialized, either alone or in partnership with others; the
Company’s estimates regarding future expenses, future revenue,
capital requirements and needs for additional financing; the
Company’s financial performance; and other risks and uncertainties
described under “Risk Factors” in the Company’s most recent Annual
Report on Form 10-K and Quarterly Reports on Form 10-Q and in the
Company’s other filings with the SEC. The Company cautions that the
foregoing list of factors is not exclusive. The Company cautions
readers not to place undue reliance upon any forward-looking
statements, which speak only as of the date made. The Company does
not undertake or accept any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
to reflect any change in its expectations or any change in events,
conditions, or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241220584164/en/
Investor Jeff Keyes Chief Financial Officer
ir@quantum-si.com Media Katherine Atkinson SVP, Commercial
Marketing media@quantum-si.com
Quantum Si (NASDAQ:QSI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Quantum Si (NASDAQ:QSI)
Historical Stock Chart
From Dec 2023 to Dec 2024